Coronary artery disease (CAD) is the most common type of heart disease, affecting millions of people around the world. Coronary artery narrowing, or stenosis, limits blood flow and decreases the supply of oxygen delivered to the heart in patients with CAD. Therefore, the fractional flow reserve (FFR) method is used to determine the severity of blood flow blockages in patients with coronary artery disease. FFR technology help physicians diagnose ischemia-inducing stenosis with more than 90% precision, allowing for better care decisions and avoiding unnecessary medical procedures.
The Asia Pacific fractional flow reserve market is witnessing fastest growth. The primary driving factor behind the market growth in the region is surge in incidence of diabetes and heart diseases in the high populous countries such as India and China. Likewise, factors such as growing old age population of the region, growing awareness regarding several preventative measures against diabetes and several heart diseases, entry of key medical device manufacturers and surge in the government initiatives to combat various heart related diseases are expected to improve the growth of the market across the APAC region.
However, lack of awareness regarding advanced medical devices related to cardiovascular diseases is major restraining factor that could hamper the growth of the market in the region.
The study analyses Asia Pacific fractional flow reserve market based on technology, application, and country.
On the basis of technology, non-invasive monitoring segment likely to witness fast growth during the estimated timeframe. A non-invasive monitoring technique allows for painless, continuous and on-line patient monitoring with a low risk of infection, as well as real-time data monitoring and clinical response to measured data. Growing technological advancements in non-invasive FFR monitoring system or devices is accredited to the growth of the market.
On the basis of application, single vessel disease segment is projected to witness fast growth during the projection period. The high prevalence of single-vessel coronary artery disease accounts for a significant share of this market. Alternatively, since multi-vessel coronary artery disease (CAD) is a more advanced form of single-vessel CAD, it is likely to improve at a faster rate over the forecast timeframe. If proper care and medications are not taken, a person with single-vessel CAD is strongly likely to experience multi-vessel CAD in the near future. This is ultimately improving the growth of the segment.
Country wise, the study is comprised of the key countries such as the China, India, Japan, and rest of the Asia Pacific. The China held the largest market share of Asia Pacific fractional flow reserve market and is likely to dominate the market over the estimated time frame. However, India is the fastest growing country in the fractional flow reserve market. Major growth factors such as the vast presence of various domestic and global medical devices manufacturing companies, suppliers and distributors, growing middle-class population, high disposable income of the people on health, changing lifestyle and eating habits of the people are attributed to the growth of the market.
The major key players of market includes Abbott Laboratories, Koninklijke Philips N.V, Boston Scientific Corporation, Acist Medical Systems (Subsidiary of Bracco Diagnostic Inc), Opsens, Inc, Heartflow, Inc, Siemens Healthineers, Pie Medical Imaging, Cathworks, Medis Medical Imaging Systems Bv, Medtronic PLC, and Terumo Corporation among others.
The study analyses Asia Pacific fractional flow reserve market based on technology, application and geography. Fractional flow reserve market by technology is segmented into invasive monitoring and non-invasive monitoring. The invasive monitoring segment is likely to dominate the Asia Pacific market over the forecast period. Increased adoption of invasive monitoring techniques and devices is attributed to the market growth. The market finds application in single-vessel diseases and multi-vessel diseases. The single-vessel diseases segment is likely to register fastest growth in years. Country wise, the study is comprised of China, India, Japan, and rest of the Asia Pacific.
Why to buy this report: